Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Biotechnology

Healthcare
$3.99 -0.81%

-$0.04 today

Market cap
$320.41M
Beta
0.32
P/E (TTM)
-2.0
EPS (TTM)
-$2.14
52W Low $2.78High $6.45

Volume 0.34M

Average 0.34M

AVIR Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Atea Pharmaceuticals, Inc.NASDAQ: AVIR

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares declines year over year

Q1 FY2026 weighted avg shares of 79.2M shares fell 7.0% year over year, behind the -5.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -7.0% toward the trailing-twelve-month pace of -5.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
79.2M+1.4% QoQ
Last fiscal yearDec 2025
81.5M-3.3% YoY
LTMMar 2026
80.03M-5.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.0%——
1 year-3.3%——
3-year CAGR-0.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
81.5M USD
Year-over-year change
-3.3%
4-year CAGR
-0.4%

Weighted Avg Shares vs competitors

How AVIR compares with its peers on the latest reported figures

  • AVIR's LTM Mar 2026 weighted avg shares of 80.03M shares is the 3rd highest of the 5 companies compared; the peer median is 81.18M shares.
  • Its year-over-year change of -5.4% is the lowest of 5, against a peer median of +2.6%.
  • Over three fiscal years its annual growth of -0.7% compares with a peer median of +4.9%.
AVIR Competitors Peer median
Weighted Avg Shares for AVIR and competitors
Company Period LTM YoY 3-year CAGR
ABUSArbutus Biopharma CorporationLTM Mar 2026192.17M +2.0%+8.3%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
Peer median (excluding AVIR) 81.18M+2.6%+4.9%

Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue351.37M0000
Cost of Revenue167.21M62.39M70.09M83.37M0
Gross Profit184.16M(62.39M)(70.09M)(83.37M)0
Gross Margin52.4%————
Research & Development167.21M88.84M132.84M145.4M148.02M
Selling, General & Admin45.79M48.71M49.92M48.85M32.86M
Operating Expenses45.79M68.26M94.07M109.58M180.89M
Depreciation & Amortization29K260K416K416K416K
EBITDA138.62M(110.84M)(119.59M)(131.8M)(164.1M)
EBITDA Margin39.5%————
Operating Income138.38M(130.65M)(164.16M)(192.95M)(180.89M)
Operating Margin39.4%————
Interest Income213K11.15M29.22M25.49M16.38M
Interest Expense011.15M000
Other Income / Expenses213K11.15M29.22M25.49M16.38M
Income Before Tax138.59M(119.5M)(134.94M)(167.46M)(164.51M)
Pre-Tax Margin39.4%————
Income Tax Expense17.4M(3.59M)1.02M925K(6.16M)
Net Income121.19M(115.91M)(135.96M)(168.39M)(158.35M)
Net Margin34.5%————
EPS (Basic)1.46(1.39)(1.63)(2.00)(1.94)
EPS (Diluted)1.37(1.39)(1.63)(2.00)(1.94)
Weighted Avg Shares82.82M83.25M83.39M84.26M81.5M
Weighted Avg Shares (Diluted)88.25M83.25M83.39M84.26M81.5M

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.